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Clinicians have been working out ways to incorporate buprenorphine into their treatment
models. Representatives of three addiction treatment programs—a Veterans Affairs
methadone clinic, a group of outpatient mental health centers, and a nationwide organiza-
tion of therapeutic communities—talk about their plans and experiences.
A VETERANS’ METHADONE CLINIC IN NEW YORK CITY
Paul Casadonte
I
have been working with and prescribing buprenorphine in a variety of settings
since the early 1990s. I was principal investigator in two large buprenorphine
research studies and study chairman for the NIDA-Veterans Affairs (VA)
Office-Based Practice Study. That experience persuaded me that buprenorphine
has potential as an alternative medication in methadone clinics for patients who
need a clinic’s structure and guidance but can benefit from the medication’s spe-
cial properties.
Our program is an integral part of the New York Harbor Healthcare System
medical center, but is geographically separate from the VA hospital. At the time
we signed our lease in the mid-1990s, this area of lower Manhattan was called the
meatpacking district and considered undesirable. Then suddenly the area began
to be redeveloped; it is now a historic district, and we have a methadone clinic
in a very desirable area, surrounded by art galleries and some of the best restau-
rants in town. Our patient census at any time is about 200, all honorably dis-
charged veterans. Many are Vietnam-era veterans; the median age is 47. Recently
a number of older veterans have come in, people in their 60s who became addicted
to pain medication in their 50s.
Patients must commit to a 60-day medicated stabilization. We no longer
accept people who want only a quick heroin detoxification, because relapse as soon
as methadone was tapered was significant. 
         SPECIAL FOCUS—COMMUNITY TREATMENT PROGRAMS TAKE UP BUPRENORPHINE • 25
During stabilization, patients get group therapy
and counseling. If they do well—not necessarily stop-
ping opiate use but keeping their appointments and
showing other evidence of commitment to therapy—
we offer them longer treatment. Patients who con-
tinue doing well for 90 days may receive methadone
on a takeout basis. Patients who are doing poorly at
60 days are informed they have 30 more days to turn
around or possibly face a taper of their medication or
transfer to a higher level of care. 
Of course we make every effort to engage patients
in treatment, but we do not tolerate drug use for
extended periods. We understand that it takes time
to change behaviors, but since heroin use is danger-
ous, we put pressure on the patient to stop quickly.
Just about all respond to our interventions, and reten-
tion is high.  
Recently we had been stabilizing everyone 
on methadone—also using LAAM (levo-alpha-
acetylmethadol hydrochloride) for over 10 years—
but now we are offering buprenorphine. Patients have
a choice. Now that LAAM is no longer available,
buprenorphine is all the more welcome.
In a private office setting or primary care clinic,
I’d be willing to offer buprenorphine to every opiate-
dependent patient, especially those addicted to pain
medications, and see who responded. Some may need
methadone maintenance in a structured clinic, but
buprenorphine is a good first choice. In our public
clinics, we need to pay close attention to cost-
effectiveness and perhaps initially reserve buprenor-
phine for patients most likely to benefit—working,
younger, lower level of addiction. I will certainly offer
it to individuals who started abusing opioids only
recently, have had no previous methadone treatment
or did not like methadone maintenance clinics, and
are functioning relatively well, with homes and jobs
and stability in their living situations and family obli-
gations. These people can benefit from the more
liberal take-home dosing that buprenorphine makes
possible. We are offering three-times-a-week visits, as
we did with LAAM. I would be less likely to offer
buprenorphine to someone who’s been abusing drugs
for many years with multiple treatment failures,
and has a history of incarceration, multiple medical
and psychiatric problems, and so forth.
I do not suggest to patients who are stable on
methadone that they transfer to buprenorphine. If
someone wants to switch, we will make sure he is deter-
mined enough to weather the bit of discomfort the
process requires. We would advise that he taper down
his methadone dose and enter into withdrawal on the
day we start the buprenorphine. Once through the
transition, buprenorphine may not fully control dis-
comfort and craving, especially for people who have
been on high methadone doses. That said, responses
are very individual. I have seen people stabilize on
buprenorphine who were using $100 per day of heroin.
We have been converting a majority of our LAAM
patients to methadone, since most of them have used
methadone in the past, at least for detoxification. A
few have wanted to try buprenorphine, and so far
these transitions generally have gone well.
The patients who get buprenorphine will follow
all the same clinic rules as everyone else, except they
will be eligible for takeouts a little more rapidly—
after 60 days, providing their urine tests are negative.
I’m not going to give take-homes to people who are
still abusing opioids, because buprenorphine will be
sold and diverted onto the street. This is inevitable,
even with Suboxone, the buprenorphine-naloxone
combination product we will be using. Out-of-
treatment opioid users won’t seek Suboxone to inject,
because that will make them sick; but they will buy
it to stave off withdrawal when they can’t get other
opioids. In the clinical trials we saw patients selling
doses or giving them away to friends for this purpose.
To minimize diversion, our nurses will monitor
how much buprenorphine is going out, lost doses,
and so on. However, directly observed treatment—
actually watching patients to make sure they ingest
the medication, as we do with methadone—is imprac-
tical with buprenorphine. The pills just take too long
to dissolve, up to 5 to 8 minutes. By the way, I’m told
they taste nasty.
The staff here is excited about buprenorphine.
My own acceptance has generated interest and excite-
ment about it. I’ve sent some staff members to train-
ings and have done many trainings myself, and that
has aroused their scientific curiosity.
Staff buy-in for any new medication is critical
and not automatic. Some of the staff may be con-
cerned that buprenorphine, by allowing patients to
come in only once a month, could jeopardize their
jobs. To put this concern in perspective: We saw sim-
ilar worries 10 years ago, when LAAM was introduced
and patients began to be able to come in only three
times weekly rather than daily. The fact is, there is
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plenty enough opioid addiction to keep everybody
working. It is a good thing if treatment providers have
to see individual patients less frequently, because it
enables us to offer treatment to more patients.
In methadone clinics, as in other treatment set-
tings, events and experience will determine how
buprenorphine ultimately is used. At present, regu-
lations inhibit methadone clinics from fully explor-
ing buprenorphine’s potential advantages, by requir-
ing us to maintain these patients on the same attendance
and monitoring schedules as our methadone patients.
Hopefully that will change. 
The current higher cost of buprenorphine com-
pared to methadone may affect public and private
methadone centers differently. At our VA clinic, we
won’t pass the extra cost on to our patients. Private
clinics may pass on costs. If they do, some patients
may think, “If I have to pay more out of pocket to get
buprenorphine in a methadone clinic, why not go to
an office-based practitioner instead?” So there are
issues to be worked through; but fundamentally, I
think buprenorphine should have a place in methadone
clinics, both public and private.
A COMPREHENSIVE OUTPATIENT 
TREATMENT PROGRAM
George Kolodner
T
he Kolmac Clinic is an outpatient chemical depend-
ency program in a mental health setting. We admit
about 600 patients a year at 3 locations and maintain
a census of 250 to 280 patients. We treat the full spec-
trum of chemical addictions, including alcohol and
cocaine addiction.
Our program is both intensive and comprehen-
sive, combining detoxification, rehabilitation, and
followup care. Patients participate for up to a year and
a half, after which they are encouraged to participate
in support groups—usually either 12-step meetings
or alternative programs like Smart Recovery. We are
now beginning to offer buprenorphine as a support
to the treatment of opiate addiction. Thus far we have
treated 130 patients.
The program appeals primarily to people of mod-
erate means who cannot afford the expense of long-
term inpatient treatment, but who have insurance
coverage and are anxious to avoid the stigma of a pub-
lic clinic. Clinic sessions take place in the evenings,
making it possible for working people to attend. We
have recently been approached by a managed care
company that works specifically with Medicaid patients,
and we are thinking of setting up a Medicaid pilot
program to see if our model will work with that pop-
ulation.    
We have been looking forward for many years
to buprenorphine’s approval. When the medication
was in clinical trials all the researchers were report-
ing how much better it was, particularly for detox,
compared to its nonnarcotic predecessors. Clonidine
and diazepam were better than cold turkey, but not
by much. Naltrexone looked like it worked, but
patients wouldn’t stay on it and they relapsed. Our
completion rates were only about 10 percent for
heroin addicts and 40 to 50 percent for prescription
drug abusers.   
We literally had patients dying—especially young,
naïve heroin users who did not understand how tol-
erance works. They would get clean for a while, then
relapse and die from an overdose because they had no
sense of how their tolerance had changed. I was becom-
ing reluctant to treat opioid addicts; on the other
hand, some of them seemed to make it, and their needs
were so acute that I didn’t feel right turning them away.
It was very frustrating to know there was a drug that
had been proven safe but was not yet available.
We initially attempted to use buprenorphine for
short-term detoxification. It worked, but our long-
term recovery rates did not improve. We concluded
that we did not want to use the medication as a short-
term expedient. We physicians want to relieve suf-
fering, but we don’t want to set up revolving-door treat-
ments. Our overall strategy is to use buprenorphine
right from the beginning to facilitate withdrawal, to
continue using it as a stabilizing medication, and to
be very cautious about taking a patient off it.
With regard to patient selection for buprenor-
phine, I won’t accept people who indicate that they
just want to use the medication for detox. Patients
have to commit to participation in our entire pro-
gram, with buprenorphine being used as a support in
the process. At this point I consider every active
opioid addict who makes that commitment a poten-
tial candidate. The exceptions are a few people who
come in who have already been through withdrawal
and are 2 to 3 weeks past their last opioid use. I
offer these people naltrexone instead of buprenor-
phine, because I have qualms about putting them back
on a narcotic. 
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Our patients’ experiences with buprenorphine
have been positive so far. Completion rates are up
sharply over our past experience with opioid abusers.
Patients who have used methadone in the past gen-
erally report that buprenorphine makes them feel
much better—they’re energetic, their heads are clear,
they can function. Of course, the former methadone
patients our clinic attracts are not from the very large
population that thrives on methadone, but those who
for some reason or another had a bad experience,
relapsed, and don’t want to try it again. 
A number of our patients have attention deficit
disorder. As far as we can tell, the buprenorphine does
not necessitate a change in their dose of stimulant
medication, and they seem to do as well as other
buprenorphine patients. 
We have had a few patients relapse while on
buprenorphine, and uniformly they’re telling me they
don’t get high. One of these was a lady who was given
20 Percocet (acetaminophen and oxycodone) in the
ER and took them all in one day.
Patients generally enter our program wanting to
use buprenorphine temporarily, with the goal of becom-
ing drug free. While, as I have said, our personal expe-
rience indicates that removing buprenorphine too
quickly invites relapse, we do not yet have sufficient
research information to tell us when in the course of
treatment we should offer or press our patients to taper
off the medication. So we resort to trial and error, tak-
ing people off the drug when it appears reasonable to
do so, and putting them back on if they relapse. But
you hate to see people relapse. The scary thing is that
things are working so well with buprenorphine, you
don’t want to rock the boat.
Because our clinic staff was already used to
giving meds for detoxification, it was easy for them
to accept the use of buprenorphine for that pur-
pose. However, they were initially ambivalent about
the idea of keeping patients on it after detox. Many
of our staff are recovering from chemical dependence
and are wary of medications. While they accepted nal-
trexone, buprenorphine, as an opioid, was a different
matter. Some of the staff had also had negative expe-
riences with drugs like diazepam and alprazolam,
which the treatment community adopted enthusi-
astically, only to find that they were cross-addicting
medications. I talked to the staff, and had someone
from one of the better methadone programs come to
talk to them. He had been on methadone himself for
many years and gotten off, so he was able to give them
the perspective of someone whose life had changed
in a positive way with opioid maintenance.
Ultimately, what really changed the staff’s atti-
tude was their experience with the patients. Having
worked with opioid patients who were not being main-
tained on opioid agonists, they saw how the people
on buprenorphine could do a higher level of work. If
you were to walk into one of our groups, you would
not be able to tell which patients are on buprenor-
phine. Now the staff is enthusiastic.
I use only Suboxone, the combination product
that also contains the opioid blocker naloxone, partly
to reduce the chances for buprenorphine diversion.
If someone injects Suboxone while having an opi-
oid other than buprenorphine on board, the nalox-
one will flush that opioid from the brain, thrusting
the patient into withdrawal. However, there is uncer-
tainty concerning whether or not someone can get
high from injecting Suboxone when no other opi-
oid is on board. Some researchers believe the nalox-
one will reach the brain first, and keep the buprenor-
phine from having any effect. But others are concerned
that buprenorphine may overpower the naloxone in
this situation and produce a high, albeit a relatively
mild one. Time will tell.
We have been pleased that the insurance com-
panies thus far have not balked at paying for buprenor-
phine. The medication’s price is not exorbitant rela-
tive to the benefit it confers. All the major insurers in
our area cover it; however, they do have several tiers
of coverage. We are working to get the drug on the
preferred list so that the copayments are reduced.  
In summary, we are finding that buprenorphine
fits very well into our program, both as a support
for detoxification and for stabilization. It is a matter
of serious concern that the medication, which has
so much potential, could fail because it may be pre-
scribed in isolation and not as part of a comprehen-
sive treatment program. 
PHOENIX HOUSE, A THERAPEUTIC 
COMMUNITY
Terry Horton and Suzanne McMurphy
P
hoenix House was founded in 1967. Today we
are the largest not-for-profit therapeutic com-
munity (TC) in the Nation. We operate some 90 drug
treatment programs serving about 5,500 clients,
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primarily on the West and East Coasts. Our New York
State program is distinguished by the fact we offer a
full complement of primary care medical services
within our abstinence-based residential program. We
provide our own medical, dental, HIV, and optome-
try care. 
At Phoenix House, we are looking at buprenor-
phine as potentially the long-awaited answer to a seri-
ous problem. In New York and elsewhere, the detox-
ification interval has historically raised a formidable
barrier to successful integration of new opioid-addicted
clients into TCs. For many years our State law allowed
only hospitals to provide opioid detoxification serv-
ices, so when patients came to us from the street we
had to send them to an offsite medical center. Fewer
than half came back. Those who did return were now
several days—hard days—distant from the resolve
that had originally brought them to our door. As well,
many were still in withdrawal, because their detoxi-
fication treatments were inadequate.
Under those conditions, treatment engagement
was difficult. Dropout rates within the first week were
extremely high. The high dropout rates associated
with offsite detoxification were financially damaging
and ethically problematic. An induction bed given to
a patient who drops out loses money for Phoenix
House and—with half a million addicts in need of
treatment in our city—wastes a vital resource.
About 5 years ago, State regulations changed to
allow community-based medical detoxification.
However, the medications available at the time were
not well suited for TCs. Methadone carries an over-
whelming regulatory burden. Clonidine has limited
effectiveness, we believe, and certainly is not popular
with addicts. So we continued to refer patients out.
Buprenorphine has finally provided us with the
tool we have needed to bring detoxification services
on site and integrate them with our other program
offerings. Our enthusiasm for the new medication
reflects firsthand experience. Phoenix House partic-
ipated in Dr. Walter Ling and Dr. Leslie Amass’s NIDA
Clinical Trials Network (CTN) study comparing
buprenorphine to clonidine for detoxification in res-
idential settings. Buprenorphine looked like a win-
ner for us: Although we treated only half a dozen
patients, they liked the medication and tolerated it
well; side effects were minimal and no serious adverse
events occurred. The staff found buprenorphine effi-
cacious and easy to administer. Based on monthly
phone conversations with the other participating 
programs, our positive experience seemed to be 
typical.
With the lessons of the study to guide us, in 2003
Phoenix House created a buprenorphine detoxifica-
tion program that we call “First Step.” Candidates are
screened in any of our outreach centers, and with
approval of our staff physician, are admitted to our
Long Island City residential facility. After the physi-
cian completes his evaluation, the patient is prescribed
and is observed self-administering the first of two ini-
tial doses of sublingual buprenorphine. Typically,
clients become comfortable so quickly that they are
able to participate in TC treatment right away, often
within hours of the first dose. They are clear-minded;
they do not nod off. Buprenorphine essentially serves
as a treatment readiness drug, bridging the void between
active drug use and drug-free treatment. From then
on, the detoxification service functions essentially as
an outpatient enhancement to a residential program.
Patients participate fully in regular treatment activi-
ties. Twice a day they walk over to the health clinic
for withdrawal symptoms assessment, dosing, and
special motivational seminars.
First Step’s protocols are based on the detoxifi-
cation schedule used in the CTN clinical trial: 
13 days of medication, building up to an 8-mg or 
16-mg maximum dose and tapering back down to
zero, followed by a final day of observation. Over time,
we have learned to individualize treatment, changing
the induction, stabilization, and tapering doses and
schedules to best and most comfortably support patient
needs. We’ve also begun treating clients on methadone
and other long-acting opioids. No empirical studies
have yet sorted out what the ideal time span for detox-
ification with buprenorphine should be, but an aver-
age of 2 weeks works well for us. That’s ample time
for clients to become engaged in the community envi-
ronment, and for the staff to administer a curriculum
of enhancements to support client motivation.  
“Seamless continuum of care” is an overused
phrase, but we honestly believe that’s what we are
achieving with First Step. Detoxification and induc-
tion are simultaneous and mutually reinforcing from
the patient’s Day 1. To date, more than 230 clients
have passed through the program. Retention and
completion rates have far exceeded our initial goals.
When we first decided to go ahead with First Step, we
imposed do-or-die criteria for viability. During the
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first 6 months, we had to beat our baseline reten-
tion rates for opioid-addicted clients successfully mak-
ing the transition from induction beds to long-term
treatment. Moreover, the program had to be finan-
cially self-sustaining. Though the program has far sur-
passed its clinical performance goals, it has yet to
achieve fiscal viability; however, we expect to reach
necessary daily census targets within the half-year.
The first prerequisite for creating a service like
First Step is having onsite medical services. A key con-
cern is integration, structuring to take advantage of
your assets—in our case, the community experience
and group dynamics of self-help and mutual support.
An important feature of First Step, for example, is that
the nonmedical team also reports to the director of
induction. That’s an unusual paradigm, because med-
ical models usually put everything under the medical
director’s authority. But it involves our induction
director in the client’s case from the very outset, and
keeps our focus on detoxification as a transitional
rather then a preliminary or separate episode in the
patient’s care.
Some issues took us by surprise when we started
First Step. Outreach was one: At first, we had trouble
attracting clients. We found we were struggling against
Phoenix House’s rock-solid, formed-in-cement rep-
utation. Throughout New York, people who refer
street addicts for treatment were used to thinking,
“Oh yes, Phoenix House, they’re abstinence-based;
the client will have to go to detox first.” Even though
providing medical detoxification is entirely consis-
tent with the abstinence-based philosophy, some refer-
ral sources had trouble picturing us doing it. Over the
past year we have placed a great deal of effort into con-
tacting referral decisionmakers—social workers, judges,
parole officers, and others—and saying: “Guess what?
We have something new at Phoenix House. Have you
heard about First Step?” &
   